Vir Biotechnology (VIR) Stock Forecast & Price Target
Score
Vir Biotechnology, Inc. price target
| VIR | |
|---|---|
| Low | $22.00 |
| Average | $23.50 |
| High | $25.00 |
| Upside vs current price | +135.9% |
The average target of $23.50 is +135.9% versus the current VIR price of $9.96.
Vir Biotechnology, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 3 |
| Buy | 6 |
| Hold | 0 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
9 analysts cover VIR.
Vir Biotechnology, Inc. EPS and revenue estimates
The estimate table for the Vir Biotechnology, Inc. keeps 2026 EPS $-1.78, 2027 EPS $-2.54, and years with fewer than three analysts are not filled in.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-1.78 | $246.03M |
| 2027 | $-2.54 | $73.41M |
Is Vir Biotechnology, Inc. a buy or sell?
Of the 9 analysts covering Vir Biotechnology, Inc., 9 rate it a buy (3 strong buy and 6 buy), 0 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The VIR consensus label is Buy, beside 9 buy-side ratings and 0 sell-side ratings.
The average target of $23.50 implies +135.9% versus the current price of $9.96.
the Vir Biotechnology, Inc. closes with 9 buy-side ratings and 0 on the sell side. The headcount is Buy.
Reading the Vir Biotechnology, Inc. forecast
There is little daylight between VIR targets. Low $22.00, average $23.50, high $25.00.
From today's $9.96 print, the VIR average target is +135.9% away.
Most of the VIR coverage agrees: 9 of 9 analysts are on the buy side, 0 are at hold, and 0 are on the sell side, and the published consensus is Buy.
VIR targets have eased: $22.00 in the last month against $23.50 over the last quarter.
VIR coverage is thin at 9 analysts, and one revision moves the average.
Vir Biotechnology, Inc. forecast questions
What is the VIR price target?
The published range for VIR is $22.00 to $25.00, with an average of $23.50. That average is +135.9% versus the current price of $9.96.
Is Vir Biotechnology, Inc. a buy or sell?
Of the 9 analysts covering Vir Biotechnology, Inc., 9 rate it a buy, 0 rate it a hold, and 0 rate it a sell. The consensus is Buy, which for VIR is 9 on the buy side, 0 at hold, and 0 on the sell side.
What is the EPS estimate for Vir Biotechnology, Inc.?
Analyst EPS estimates for Vir Biotechnology, Inc.: 2026 $-1.78, 2027 $-2.54.
What is the revenue estimate for Vir Biotechnology, Inc.?
Analyst revenue estimates for Vir Biotechnology, Inc.: 2026 $246.03M, 2027 $73.41M.
How many analysts cover VIR?
9 analysts cover VIR. Their consensus on VIR is Buy, across those 9.